Tridek One, Paris, June 4, 2019 ‐ Tridek One, a biotech company specialized in the development of products for the treatment of immune disorders, is pleased to announce a first round of funding of 3 million euros with leading investors Advent France Biotechnology and Advent Life Sciences.
Tridek One was founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148 (Team 1), together with Advent France Biotechnology. Tridek‐One is developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions.